Company intelligence / Profile preview
Galmed Pharmaceuticals
Ramat Gan / Tel Aviv, Tel Aviv District, Israelgalmedpharma.com ↗
- Ownership
- Public · GLMD
- Employees
- ~6
- Development stage
- Phase 3
01
Overview
Galmed’s lead compound Aramchol has shown promising results in reducing markers of systemic inflammation and liver fibrosis in NASH patients. The company recently unveiled novel pharmacodynamic blood markers that may serve as early indicators of efficacy. Clinical trial data have driven recent market optimism and strategic partnerships with research hospitals. The company’s financials show improved liquidity but ongoing need for capital
- Therapeutic areas
- GastroenterologyCardiovascularImmunologyOncologyInfectious Diseases
- Modalities
- small molecules (notably synthetic fatty acid-bile acid conjugates)peptides
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Samil Pharma Co., Ltd. (commercialization of Aramchol in South Korea)OnKai (AI platform collaboration)Proteas Health (biomarker assay development)
04
Financials
- Market cap
- $4.8M
- Total revenue
- $0
- Enterprise value
- $-6.5M
Beyond the preview
Go deeper on Galmed Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Galmed Pharmaceuticals.